Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 21 studies | 85% ± 15% | |
lung | 20 studies | 79% ± 20% | |
intestine | 13 studies | 81% ± 19% | |
brain | 11 studies | 45% ± 25% | |
kidney | 9 studies | 82% ± 17% | |
eye | 9 studies | 50% ± 21% | |
liver | 8 studies | 67% ± 26% | |
bone marrow | 6 studies | 77% ± 14% | |
lymph node | 6 studies | 89% ± 6% | |
heart | 5 studies | 37% ± 18% | |
uterus | 5 studies | 84% ± 20% | |
prostate | 5 studies | 72% ± 29% | |
pancreas | 4 studies | 79% ± 19% | |
placenta | 4 studies | 87% ± 21% | |
adipose | 4 studies | 54% ± 25% | |
esophagus | 4 studies | 66% ± 28% | |
breast | 4 studies | 90% ± 6% | |
adrenal gland | 3 studies | 79% ± 15% | |
skin | 3 studies | 77% ± 19% | |
stomach | 3 studies | 55% ± 21% | |
thymus | 3 studies | 84% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 16034.08 | 258 / 258 | 100% | 78.15 | 230 / 230 |
liver | 100% | 10494.55 | 226 / 226 | 100% | 77.10 | 406 / 406 |
ovary | 100% | 7655.95 | 180 / 180 | 100% | 77.51 | 430 / 430 |
thymus | 100% | 12497.30 | 653 / 653 | 100% | 80.45 | 605 / 605 |
uterus | 100% | 8878.95 | 170 / 170 | 100% | 94.78 | 459 / 459 |
skin | 100% | 11297.94 | 1808 / 1809 | 100% | 80.87 | 472 / 472 |
prostate | 100% | 13456.51 | 245 / 245 | 100% | 119.43 | 500 / 502 |
esophagus | 100% | 10383.99 | 1445 / 1445 | 99% | 38.61 | 182 / 183 |
brain | 100% | 6075.71 | 2635 / 2642 | 100% | 46.93 | 703 / 705 |
kidney | 100% | 13827.11 | 89 / 89 | 99% | 60.25 | 896 / 901 |
pancreas | 100% | 7127.35 | 328 / 328 | 99% | 78.59 | 177 / 178 |
intestine | 100% | 10801.05 | 966 / 966 | 99% | 82.67 | 524 / 527 |
lung | 100% | 11627.26 | 578 / 578 | 99% | 69.63 | 1145 / 1155 |
bladder | 100% | 9943.81 | 21 / 21 | 99% | 87.50 | 499 / 504 |
breast | 100% | 10173.07 | 459 / 459 | 99% | 85.26 | 1103 / 1118 |
stomach | 100% | 9709.64 | 359 / 359 | 99% | 63.39 | 282 / 286 |
adipose | 100% | 10397.09 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 112.29 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 143.46 | 29 / 29 |
peripheral blood | 100% | 12763.70 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 11723.26 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 61.55 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 183.90 | 1 / 1 |
heart | 100% | 10996.33 | 860 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 12103.17 | 1332 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 6107.35 | 793 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0031648 | Biological process | protein destabilization |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0003674 | Molecular function | molecular_function |
Gene name | SERF2 |
Protein name | Small EDRK-rich factor 2 Small EDRK-rich factor 2 (Gastric cancer-related protein VRG107) (Protein 4F5-related) (4F5rel) (h4F5rel) |
Synonyms | FAM2C |
Description | FUNCTION: Positive regulator of amyloid protein aggregation and proteotoxicity . Induces conformational changes in amyloid proteins, such as HTT, driving them into compact formations preceding the formation of aggregates . . |
Accessions | ENST00000409614.1 [P84101-4] ENST00000339624.9 [P84101-3] F8WBN3 ENST00000430901.1 C9JQZ0 ENST00000409617.6 ENST00000630046.2 ENST00000409646.5 B8ZZY7 P84101 ENST00000402131.5 [P84101-4] ENST00000403425.5 [P84101-4] ENST00000409291.5 B9A031 ENST00000381359.5 [P84101-1] ENST00000448830.2 F8WBV6 ENST00000445816.5 [P84101-1] ENST00000409960.6 [P84101-2] ENST00000249786.9 [P84101-1] |